Singapore markets close in 3 hours 16 minutes

Bioventus Inc. (BVS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.3900-0.1600 (-3.52%)
At close: 04:00PM EST
4.2700 -0.12 (-2.73%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close4.5500
Open4.5500
Bid0.0000 x 800
Ask0.0000 x 800
Day's range4.3100 - 4.5952
52-week range0.8000 - 5.5430
Volume141,217
Avg. volume161,616
Market cap276.42M
Beta (5Y monthly)0.47
PE ratio (TTM)N/A
EPS (TTM)-2.5600
Earnings date29 Mar 2024 - 02 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.50
  • GlobeNewswire

    Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

    DURHAM, N.C., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has entered into an Amendment No. 5 (the “Amendment”) to the Credit and Guaranty Agreement, between the Company, Wells Fargo Bank, National Association as Administrative Agent and Collateral Agent, and the Lenders from time to time party thereto, dated as of December 6, 2019 and as amended on August 29, 2021, Octob

  • GlobeNewswire

    Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole

    DURHAM, N.C., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the issuance on January 11, 2024 of previously disclosed inducement equity awards to Robert (Rob) Claypoole in connection with this appointment as President and Chief Executive Officer, and Principle Executive Officer of the Company. The awards consist of 375,000 restricted share units and options to purchase 850,000 share

  • GlobeNewswire

    Bioventus Names Robert Claypoole as President and Chief Executive Officer

    Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Revenue and Operating Margin GrowthDURHAM, N.C., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that its Board of Directors has appointed Robert (Rob) Claypoole as Bioventus’ President and Chief Executive Officer and a member of its Board of Directors, effective January 10, 2